CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

To date, the Food and Drug Administration (FDA) has approved seven chimeric antigen receptor-T (CAR-T) cell therapies and seven bispecific T-cell engagers (BiTEs) across a variety of hematologic ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing their ability to infiltrate solid tumours.

In the last decade, a new immunotherapy tool has entered the clinic. T cells engineered to express chimeric antigen receptors, known as CAR T cells, have been shown to help patients with blood cancer.

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

In the clinical battle against leukemia, recent breakthroughs in chimeric antigen receptor T ... studies have suggested that CAR T cells that target CD123 (CART-123) could be effective.

GloboCare announced that it has been granted the patent right and Certificate of Invention for its CAR-T and CAR-NK cell ...

ViroCell Biologics ("ViroCell" or the "Company"), a specialist viral vector Contract Development and Manufacturing ...